We are proud to announce that Dr Luria Founou, PhD our Head of Research has been awarded the Cambridge-Africa ALBORADA Research Fund 2025/2026 for the project entitled “Building Capacity for Facility-Based Genomic Surveillance to Curb Neonatal Sepsis and Antimicrobial Resistance in Cameroon (#BEACON)”.

The #BEACON project will strengthen facility-based Genomics surveillance to improve early detection, tracking, and response to antimicrobial-resistant pathogens driving neonatal sepsis, leading causes of newborn mortality in sub-Saharan Africa.

This achievement powered by a visionary collaboration between Prof. Nick Thomson and Dr Mat Beale both from Wellcome Sanger Institute and Dr. Luria Founou, PhD from reinforces our role in translating science into public health impact.

Why This Matters:

Treating neonatal sepsis requires more than just medicine; it requires precision. By merging the genomic strengths of the Wellcome Sanger Institute with the local diagnostic leadership of , we are identifying infection drivers and antimicrobial resistance as they happen.

A heartfelt thank you to the Cambridge-Africa-Alborada Research Fund for investing in global health equity. Together we are ensuring that every child, regardless of where they are born, has the chance for a healthy start.